Completed PHASE2 INTERVENTIONAL 1-arm NCT02448329

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Sponsor: Samsung Medical Center

Conditions Advanced Gastric Adenocarcinoma

Updated 10 times since 2017 Last updated: Jun 13, 2022 Started: Jan 14, 2015 Primary completion: Dec 31, 2019 Completion: Apr 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02448329, this PHASE2 trial focuses on Advanced Gastric Adenocarcinoma and remains completed. Sponsored by Samsung Medical Center, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Oct 2021 — Jul 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 5 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE2
Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea